$145 million pharma acquisition to help launch opioid overdose drug
Indivior’s $145 million acquisition of Opiant Pharmaceuticals will support the launch of OPNT003, an opioid overdose reversal agent.
List view / Grid view
Indivior’s $145 million acquisition of Opiant Pharmaceuticals will support the launch of OPNT003, an opioid overdose reversal agent.
Under the contract, IRISYS LLC will develop a new, injectable formulation of drinabant that can rapidly and effectively reverse the symptoms of Acute Cannabinoid Overdose (ACO).